Investor Presentation Full Year 2021 slide image

Investor Presentation Full Year 2021

112 Investor presentation Full year 2021 Innovation drives largest transition in the history of Novo Nordisk USA, turning around 70% of sales in just seven years Directional growth drivers and catalysts 100% GLP-1 Obesity Insulin Biopharm 80% • OzempicⓇ launch RybelsusⓇ launch Victoza® LoE • WegovyⓇ launch • SaxendaⓇ LOE Continued price pressure Competitive 60% pressure • Biosimilar competition New product launches 40% 20% 1 Modern insulin, human insulin, PrandinⓇ, devices and needles; 2 OzempicⓇ and Rybelsus®, 3 TresibaⓇ, Xultophy, FiaspⓇ and follow-on brand insulin LoE: Loss of exclusivity 0% NAO Relative sales composition - 60% transformation complete ILLUSTRATIVE 2015 Biopharm Mature insulin¹ 2022 Victoza® Obesity New GLP-1 launches² New insulin launches³ 30%
View entire presentation